OMP #M#

Related by string. * Omps . OMPS . OM PD : OMP #R# . Profiler Suite OMPS . OMP designation . Larry T. Omps . Prime OMP . Platform OMP . Omps Funeral Home . OMP / #M# [002] . #m# [002] . #m#s [002] . #m#s [001] . #m# [003] . #M# [004] . #m# [004] . #m# [006] . #m# [001] : Tu #M# Backfire . Tu #M# bombers . Saskatoon SK S7K #M# . Moncton NB E1C #M# . Tu #M# . Ottawa K2C #M# . #m# ½ f . Alberta T2P #M# * *

Related by context. Frequent words. (Click for all words.) 72 HGS ETR1 71 pertuzumab 71 Sym# 71 OXi# 70 MEK inhibitor 70 CCX# 70 EZN 70 Azedra 69 CA4P 69 RGB # 69 pharmacodynamic effects 69 CR# vcMMAE 69 Imprime PGG 69 Carfilzomib 69 PARP inhibitor 68 xenograft models 68 talabostat 68 novel anticancer 68 ATL# [001] 68 deforolimus 68 antitumor 68 Irinotecan 68 angiogenesis inhibitor 68 proteasome inhibitors 68 GRN#L 68 Phase Ib clinical 68 GLPG# 68 Voreloxin 67 Doxorubicin 67 orally bioavailable 67 PXD# 67 anticancer compound 67 elotuzumab 67 MLN# 67 IMC A# 67 thymalfasin 67 Zolinza 67 eniluracil 67 Bavituximab 67 nanoviricides 66 HuMax CD# 66 romidepsin 66 CYC# 66 Bortezomib 66 vitro experiments 66 SPC# [001] 66 Phase 1b trial 66 APOPTONE 66 anticancer compounds 66 tyrosine kinase inhibitor 66 OncoVEX GM CSF 66 Elesclomol 66 MGCD# [001] 66 generation antisense 66 BAY #-# 66 immunomodulator 66 Monoclonal Antibody 66 Perifosine 66 antiangiogenic 65 BNC# 65 ALN TTR# 65 humanized anti 65 goserelin 65 therapeutic monoclonal antibodies 65 antisense drug 65 antitumor activity 65 immunomodulatory 65 Amrubicin 65 radiolabeled 65 PLX# 65 imetelstat 65 bleomycin 65 atacicept 65 BrachySil 65 seliciclib 65 PEGylated 64 BiTE antibody 64 Onalta 64 Nexavar ® 64 immunotherapeutics 64 ProLindac 64 HER2 positive metastatic breast 64 vivo efficacy 64 Cloretazine R VNP#M 64 tanespimycin 64 drug conjugate 64 AVE# 64 SCH # 64 LY# [003] 64 ZD# [001] 64 Hsp# inhibitors 64 BAL# [001] 64 Aurora kinase 64 anticancer agent 64 Phase III Clinical Trial 64 TG# [001] 64 #ME# 64 relapsed multiple myeloma 64 DAVANAT 64 BMS # 64 administered subcutaneously

Back to home page